This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kershaw, M. H. Articles by Hwu, P. Search for Related Content PubMed PubMed Citation Articles by Kershaw, M. H. Articles by Hwu, P.

Immunization against Endogenous Retroviral Tumor-associated Antigens¹

Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 [M. H. K., W. M., G. W., W. W. O., R. L., J. C. Y., N. P. R., P. H.]; Howard Hughes Medical Institute-NIH Research Scholars Program, Bethesda, Maryland 20814 [C. H., L. L. P.]; and Center for Cell and Gene Therapy, Department of Immunology, Baylor College of Medicine, Houston, Texas (R-F.W.)

Endogenous retroviral gene products have been found in some human tumors, and therefore, may serve as antigens for immunotherapy approaches. The murine colorectal carcinoma CT26 and melanoma B16 have recently been found to express the endogenous retroviral gene products gp70 and p15E, respectively, that can serve as antigens recognized by T cells. To date, though, there has been no demonstration of tumor treatment using an endogenous retroviral protein. In this study, we demonstrate that mice immunized with recombinant vaccinia encoding the gp70 H2-L^d-restricted minimal determinant were protected from CT26 tumor challenge. Splenocytes from mice immunized with vaccinia gp70 specifically secreted IFN- in response to gp70 peptide-pulsed stimulators. Although this strategy could protect against subsequent tumor challenge, it was ineffective against established tumors. Therefore, to investigate the treatment of established CT26 or B16 lung metastases, mice were treated with cultured dendritic cells (DCs) pulsed with gp70 or p15E peptide. Significant inhibition of established lung metastases required immunization with peptide-pulsed DCs pretreated with CD40 ligand that has been demonstrated to increase the T-cell stimulatory activity of DCs. The ability to immunize against endogenous retroviral tumor antigens may have relevance in the induction of antitumor immunity for some human cancers.

This article has been cited by other articles:

				K. A. Andrew, H. M. A. Simkins, S. Witzel, R. Perret, J. Hudson, I. F. Hermans, D. S. Ritchie, J. Yang, and F. Ronchese Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes In Vivo J. Immunol., December 15, 2008; 181(12): 8356 - 8362. [Abstract] [Full Text] [PDF]

				K. E. Matthews, J. S. Qin, J. Yang, I. F. Hermans, M. J. Palmowski, V. Cerundolo, and F. Ronchese Increasing the Survival of Dendritic Cells In Vivo Does Not Replace the Requirement for CD4+ T Cell Help during Primary CD8+ T Cell Responses J. Immunol., November 1, 2007; 179(9): 5738 - 5747. [Abstract] [Full Text] [PDF]

				R. Schirmbeck, P. Riedl, M. Kupferschmitt, U. Wegenka, H. Hauser, J. Rice, A. Kroger, and J. Reimann Priming Protective CD8 T Cell Immunity by DNA Vaccines Encoding Chimeric, Stress Protein-Capturing Tumor-Associated Antigen J. Immunol., August 1, 2006; 177(3): 1534 - 1542. [Abstract] [Full Text] [PDF]

				D. G. Brockstedt, M. A. Giedlin, M. L. Leong, K. S. Bahjat, Y. Gao, W. Luckett, W. Liu, D. N. Cook, D. A. Portnoy, and T. W. Dubensky Jr. Listeria-based cancer vaccines that segregate immunogenicity from toxicity PNAS, September 21, 2004; 101(38): 13832 - 13837. [Abstract] [Full Text] [PDF]

				V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, B. Macino, O. Marin, and P. Zanovello Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase J. Immunol., December 15, 2003; 171(12): 6396 - 6405. [Abstract] [Full Text] [PDF]

				A. Rosato, S. D. Santa, A. Zoso, S. Giacomelli, G. Milan, B. Macino, V. Tosello, P. Dellabona, P.-L. Lollini, C. De Giovanni, et al. The Cytotoxic T-Lymphocyte Response against a Poorly Immunogenic Mammary Adenocarcinoma Is Focused on a Single Immunodominant Class I Epitope Derived from the gp70 Env Product of an Endogenous Retrovirus Cancer Res., May 1, 2003; 63(9): 2158 - 2163. [Abstract] [Full Text] [PDF]

				J. Rice, S. Buchan, and F. K. Stevenson Critical Components of a DNA Fusion Vaccine Able to Induce Protective Cytotoxic T Cells Against a Single Epitope of a Tumor Antigen J. Immunol., October 1, 2002; 169(7): 3908 - 3913. [Abstract] [Full Text] [PDF]